CDSCO Approves Durvalumab for Muscle-Invasive Bladder Cancer
In News
What Happened
Why It Matters
Background
History & Context
What Changed
- ▶
BEFORE: Treatment for muscle-invasive bladder cancer primarily relied on standard chemotherapy and surgery, lacking targeted immunotherapy options during the perioperative phase. NOW: Durvalumab is introduced as the first perioperative immunotherapy for this condition in India.
- ▶
BEFORE: Standard surgical and chemotherapy regimens saw higher rates of disease recurrence and progression. NOW: The addition of the Durvalumab regimen offers a 32 percent reduction in the risk of disease progression, recurrence, or death.
- ▶
BEFORE: Overall survival at two years with standard care in the pivotal clinical trial was 75.2 percent. NOW: Overall survival at two years for patients treated with the Durvalumab regimen reached 82.2 percent.
Prelims Angle
NCERT Connection
Practice Questions
Q1
With Reference ToWith reference to the drug Durvalumab recently approved by CDSCO for muscle-invasive bladder cancer, consider the following statements: 1. It acts as an immune checkpoint inhibitor by binding to the PD-L1 protein. 2. It is a broad-spectrum antibiotic used to prevent post-surgical infections in cancer patients. Which of the statements given above is/are correct?